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Abstract
Problem: Currently used standard treatments (Chemotherapy, radiation) in cancer
patients are generally accompanied with side effects, which may include pain, nausea,
vomiting, fatigue, and chemotherapy-induced peripheral neuropathy (CIPN) during and
after completion of treatments. High dose IV C may improve the anti-cancer action of
chemotherapeutic agents by reducing side effects of fatigue, pain, nausea and vomiting
and boosting immune cell functioning, and inhibiting angiogenesis (Mikirova, Casciari,
& Hunninghake, 2019).The purpose of this quality improvement project was to explore
whether high dose intravenous vitamin C (IV C) prevented major side effects that
frequently occur with standard treatments in cancer patients and measure quality of life.
Methods: An observational, descriptive, cohort study utilizing a retrospective medical
record review. A Plan-do-study-act (PDSA) cycle was utilized to evaluate the
effectiveness of IV C in cancer patients.
Results: A total number of twenty (N=20) charts of participants who received IV C
therapy for different types of cancer were reviewed. There were fourteen females (N=14,
70%) and six males (N=6, 30%) who underwent the therapy. Seven (N=7, 35%) of the
patients received IV C/Traditional and thirteen (N=13, 65%) received IV C only. None of
the participants reported any side/adverse effects to IV C and all reported improved
quality of life.
Implications: There were little to no side/adverse effects noted to this study, therefore IV
C could be an appropriate alternative or adjunct therapy to treat cancer patients.
Monitoring these patients for a longer period of time may yield more beneficial results
and improved quality of life.
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Millions of people continue to be diagnosed and live with cancer which is the
second most prevalent terminal disease around the world today (American Cancer
Society, [ACS], 2019). Statistics show that, lung, breast, and prostate cancer top the chart
for the highest mortality rate (ACS, 2019). Lung cancer has the highest mortality of 56%
for a five-year survival rate (Siegel, Miller & Jemal, 2018). Lung cancer has 228,820 new
cases and 135,720 deaths were estimated in 2020; there were 279,100 new cases of breast
cancer which is the most prevalent cancer in women in the US with 42,690 deaths
recorded to date. Prostate cancer has a total number of 191,930 new cases and 33,330
deaths to date in the US (ACS, 2019).
It is estimated that between 19% to over 85% of cancer patients are affected by
antineoplastic agents, causing chemotherapy induced peripheral neuropathy (CIPN) and
leading to motor and autonomic damage to the body which gradually unfolds over the
years after treatment (Zajączkowska, Kocot-Kępska, Leppert, Wrzosek, Mika,
Wordliczek, 2019). Cancer patients undergo major side effects including pain, fatigue,
nausea, and vomiting which are very common when treated with traditional/conventional
treatments. The use of high dose IV C for cancer patients has been used for many decades
by complimentary alternative medicine (CAM) providers with few side effects reported.
Statistics show that out of the 9,328 patients surveyed, only 1% reported minor side
effects (Carr & Cook, 2018).
In 2012, there were 14.1 million new cases and 8.2 million cancer-related deaths
worldwide. In the year 2019, 57% of new cancer cases occurred in less developed regions
of the world. These include Central America, Asia, and parts of Africa.
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Statistics show that 65% of deaths are due to cancer. The number of new cancer cases per
year is expected to rise to 23.6 million by 2030 globally (ACS, 2019).
Statistics from the (Centers for Disease Prevention and Control [CDC], 2019),
noted that, a total number of 1,658,716 new cases of cancer were reported in the United
States alone. The new cases involved; 833,308 male, and 825,408 female patients. The
overall incidence was reported as 436 per 100,000 people in which 471 per 100,000 were
reported in males and 413 per 100,000 were reported in females (CDC, 2019). In view of
these statistics, it can be fairly concluded that, cancer has a major grip on the lives of
different populations, (African Americans, Caucasians, American Indians, etc.) the
community and the entire country as the increase in mortality rate for cancer is growing
daily, drastically affecting the US population as well as the entire world. This is a cause
for concern in healthcare as researchers and healthcare professionals are working to
educate the public about preventative measures to protect the lives of individuals who
have not contracted cancer and also to cure or manage this disease to promote quality of
life for individuals with cancer.
Treatments such as Chemotherapy, Radiation, and Surgery, are the most
recognized treatments in society today as most physicians and patients consider these
their best treatment options and generally do not consider using CAM. (Klimant, Wright,
Rubin, Seely, & Markman, 2018). The use of traditional treatments for cancer have been
proven effective, but also cause side effects. Pain, fatigue, nausea, and vomiting are
among the commonly reported side effects in patients undergoing chemotherapy
treatment (Ince & Yildirim, 2019). Despite the use of antiemetic drugs as a standard
treatment to prevent nausea and vomiting before and after chemotherapy, it is reported
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that, more than 60% and 45% of patients suffer nausea and vomiting respectively, 70%
and 55% were reported to suffer from fatigue and pain respectively (Ince & Yildirim,
2019). The rates at which these major side effects occur in the lives of cancer patients is
alarming, bringing importance to consideration of what can be done to reduce these
burdensome side effects in the lives of cancer patients (Ince & Yildirim, 2019).
More than 15 million Americans living today have a history of cancer (ACS,
2019). This disease takes a significant toll on the health of patients and their families and
may also constitute a financial burden to the patients and their families as well. It was
estimated that cancer patients paid nearly $4 billion out-of-pocket expenses for traditional
treatment in 2014 (ACS, 2019). Cancer represents a significant proportion of total U.S
health care spending. In 2014, $3.0 trillion was spent on healthcare in the US.
Approximately $87.8 billion (2.93% of the total money spent on healthcare) was spent on
cancer-related care (ACS, 2019).
The purpose of this project was to observe whether IV C used as a treatment
method can reduce the major side and adverse effects of chemotherapy and radiation
treatments in cancer patients. In order to measure the effect of high dose IV C in cancer
patients, the use of European Organization for Research and Treatment of cancer
(EORTC QLQ-C30) questionnaire was used to determine side effects which included
fatigue, pain, nausea, and vomiting during and after the completion of treatment in cancer
patients. The questions for study were:
1. In patients living with cancer, what is the effect of IV C treatment on side and
adverse effects?
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2. In patients living with cancer, what is the effect of IV C on quality of life
(based on the EORTC QLQ-30 responses to questionnaire).
Literature review
The literature review for this project was carried out using different scholarly
search engines through the University of Missouri-Saint Louis electronic library
webpage. The scholarly websites includes Ovid MEDLINE, Psychological information
(PsychINFO), CINHAL, and Public/publisher MEDLINE (PubMed). Databases articles
searched range from 2015 to 2020 in which yielded 10 articles. The search was refined
using the key terms to include; cancer and CAM treatments, IV C and cancer care, CAM
care in cancer patients, side effects in cancer using the Boolean operators AND and OR.
Inclusion criteria were adult cancer patients who were undergoing traditional treatment
therapy, adult cancer patients between the ages range of 30 to 80 years of age, adult
patients of different ethnicities diagnosed with cancer receiving treatment. Studies
included treatment therapy that reduces side and adverse effects in cancer patients to
enhance quality of life. Two articles were included in the literature review.
The core quality of life (CQOL) in patients living with cancer who are being
treated with traditional care alone (chemotherapy, radiation, etc.) may be complicated by
side effects such as pain, fatigue, nausea and vomiting. The use of IV C is a safe
supportive intervention to decrease inflammation in the patient and to improve side
effects (Klimant, et al. 2018). Studies that have already explored the effects of IV C in
supportive care have design flaws such as small sample sizes. Length of the effect of an
individual IV C treatment was unknown. Studies designed to test that factor could be
useful in creating evidence-based guidelines for optimal or sustained improvement in
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CQOL (Klimant, et al., 2018). There was limited high-quality clinical evidence on the
safety and effectiveness of IV C. The existing evidence was preliminary and cannot be
considered conclusive but was a suggestive of a good safety profile and potentially
important antitumor activity; however, more rigorous evidence is needed to conclusively
demonstrate these effects. IV C may improve the quality of life and symptom severity of
patients with cancer, and several cases of cancer remission have been reported (Klimant,
et al., 2018). High dose ascorbic acid may improve the anti-cancer action of
chemotherapeutic agents, boost immune cell functioning, and inhibit angiogenesis
(Mikirova, Casciari, & Hunninghake, 2019).
In order to improve the quality of care in cancer patients, health care professionals
need to understand how the disease and its traditional treatment affect cancer patients'
health-related quality of life (HRQOL). The EORTC-C30 questionnaire was used to
measure the HRQOL in cancer patients (Chantal, Coens, Ghislain, Zikos, Mirjam,
Ringash, & Ediebah, 2015). The EORTC-C30 incorporates five functioning scales
(Physical, role, cognitive, emotional, and social functioning) and three symptom scales
(fatigue, pain, and nausea/vomiting) to measure the effectiveness of treatment regimens
in cancer patients (Chantal, et al., 2015). The use of this questionnaire enhanced better
understanding of treatment regimens for cancer patients and the need to provide a better
care and treatment plans.
In patients receiving chemotherapy treatments to manage cancer, it is reported
that cancer-related fatigue, pain, nausea, and vomiting are the most common and
debilitating side effects experienced by these patients (Peoples, Roscoe, Block, Heckler,
Ryan, Mustian, & Dozier, 2017).
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The prevalence and severity of these side effects are much higher in cancer patients
undergoing chemotherapy than other therapies. It is reported that these side effects
(fatigue, pain, nausea, and vomiting) interfere with physical, mental, social well-being,
and often impact the patient’s ability to tolerate treatment. The side effects result in
diminished quality of life and treatment discontinuation. Statistics showed that, 58% to
94% of cancer patients reported these side effects during chemotherapy. The prevalence
of these side effects are listed accordingly; fatigue-95%, pain-80%, nausea-75% and
vomiting-72% (Peoples, et al., 2017).
Chemotherapy drugs are calculated based on body surface area, which leads to
large interpatient variability of drug clearance and marked interpatient differences in
toxic effects (Foukakis, Minckwitz, Bengtsson, Brandberg, Wallberg, & Singer, 2016).
Breast cancer is the most prevalent cancer in women and the standard chemotherapy
treatment is usually cycles of fluorouracil and epirubicin-cyclophosphamide bi-weekly
depending on the stages of the disease. Most patients undergoing the traditional treatment
suffer side effects; nausea; 31%, vomiting; 46%, fatigue; 75%, pain 80%. Other side
effects suffered by these patients include diarrhea; 40%, oral mucositis; 33%, motor
neuropathy; 6%, and sensory neuropathy; 13% (Foukkais, et al., 2016).
The administration of IV C in cancer patients has generated controversies and has
not been supported by traditional treatment physicians and insurance companies. IV C
therapy has been proven useful and beneficial for the control of major side effects in
cancer patients receiving traditional treatment (Klimant, et al., 2018). Doses range from
10 g to 25 g diluted in sterile water 150 ml to 500 ml given between 30 to 60 minutes.
Reports showed that, diagnosed advanced cancer patients, including those undergoing
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chemotherapy, who received doses of 12.5–100 g IV C given at a rate of 0.5–1.0 g per
minute twice weekly for 4 weeks shows significant decreases in fatigue, nausea,
vomiting, insomnia, and constipation after 2 weeks, and a reduction in pain after 4 weeks
(Klimant, et al., 2018). The baseline mean global health status score of 44.6 improved to
61.4 after 4 weeks of IV C treatment. Reports also indicated that, there was tremendous
improvement in quality of life (QOL) as evidenced by EORTC-C30 in patients, and no
adverse events were reported. The major issue with this therapy was financial constraint
as patients undergoing this therapy paid bills out of pocket. The only side effect which
was reported by 1% of patient receiving this therapy was thirst during treatment. This
was controlled by drinking water during administration of treatment (Klimant, et al.,
2018).
The Plan-Do-Study-Act cycle (PDSA) is a framework tool used by clinicians to
measure the ongoing effort and assessing the quality of work delivered by healthcare
professionals (Christoff, 2018). In the PDSA cycle during this project, the learning and
improvement outcome was attained by testing two therapies using the process and
outcome method. The outcome measure aids maximum understanding of how effective
the IV C was by the result. The implementation of PDSA cycle utilized during this
project was a useful tool for determining improvement in treatment.
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Method
Design
This was a quality improvement project. The study design in this project was
observational cohort in which the researcher only observes the treatment result without
participating nor intervening.
Setting
The setting for this project was an outpatient treatment facility that specializes in
the treatment of different diseases such as cancer with functional medicine and CAM to
address the underlying cause of diseases at an urban, Midwestern Institute of Natural
Health. This clinic is using a systems-oriented approach which included patient-centered
care, scientific-based healthcare approach and integrating best medical practices to
provide CAM treatments to patients. This organization employs 14 healthcare
professionals who have provided care and treatments to over 150 patients for four years.
Sample
Participants included patients who are living with cancer between the age of 3080 years old, and currently undergoing cancer treatment. This study included a
convenience sample of a total of 20 male and female adults between the ages of 30 – 80
years.
Procedures
In November 2019, a team of stakeholders was formed that included a nurse
practitioner, nurses, and medical assistant. There were several meetings regarding the
discussion of information related to how the use of IV C was beneficial to cancer
patients. A decision was made to utilize and implement the EORTC QLQ-C30
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questionnaire to determine whether patients undergoing IV C therapy had side effects
such as pain, fatigue, nausea and vomiting during and after treatment. The information
will be used to develop educational training and educate clinicians performing IV C
therapy.
Approval Process
Initial approval was obtained from the Institute of Natural Health. Additional
approvals were obtained from the doctoral committee, the university institute review
board (IRB) and the final approval from the university graduate school. There was no risk
associated with this project nor any ethical considerations.
Data Collection and Analysis
EORTC QLQ-30 was used for data collection (Appendix A). Data were collected
via a retrospective medical record review from March 2020 to May 2020. The
demographic data included age, race/ethnicity, and type of cancer. Data was coded and
identified. Data included type of treatment therapy completed, and the result after the
treatment. The data collected was stored with a password protected on a computer and a
thumb drive by the primary investigator. The data collected was analyzed using
descriptive and inferential statistics to answer questions, and make recommendations.
The data was analyzed using Intellectus Statistics. Descriptive statistics and t-test were
used to measure the outcomes.
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Results
A total number of twenty (N=20) charts of patients who underwent IV C, IV
C/Traditional therapy for different types of cancer were reviewed. The age ranged from
30-80 years. A majority of the patients were female (N=14, 70%), 9 of them were
Caucasian, 4 of them were African American and 1 of them was Hispanic. The other
patients were male (N=6, 30%) of which 3 were Caucasian and the other 3 were African
American (Appendix B).
Seven (N=7, 35%) of the charts for patients who underwent IV C/Traditional
therapy reported little to no pain, no nausea/vomiting, and no fatigue on the therapy
(m=0.85, SD=0.04), (Appendix B). The charts also revealed that, each patient reported
improved quality of life. Thirteen (N=13, 65%) of the charts for patients who underwent
IV C therapy reported little to no pain, no nausea/vomiting, and no fatigue (m=0.92,
SD=0.02), (Appendix C) since they have been on this therapy. The charts also revealed
that, these patients reported improved quality of life.
Paired t-tests were calculated within each pair of measurements to examine the
differences among the variables. Comparisons were conducted for all significant effects
based on an alpha of 0.05. For the main effect of Treatment type, the mean of Treatment
outcome for CAM (M = 0.92, SD = 0.02) was significantly larger than for
CAM/Traditional (M = 0.85, SD = 0.04), p < .001. Although the sample size was small,
the patients undergoing CAM/Traditional treatment reported a significant improvement
as p <. 001 (Appendix C).
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Discussion
The study was implemented within a 12-week period. Participants included 20
cancer patients who underwent IV C, IV C/Traditional treatment for different types of
cancer, have different comorbidities as stated on their chart (See appendix B) and were
being assessed for side/adverse effects during the time frame.
The 20 participants, (N=20, 100%) reported little to no pain, and none of them reported
nausea/vomiting and or fatigue during their treatment process. This demonstrated that, IV
C had positive effects in cancer patients.
There was improved quality of life in the cancer patients as reported by the EORTC
questionnaire and histogram table (Appendix D). The results also suggested that, the use
of EORTC is a very useful tool to measure the quality of life and or side/adverse effects
in cancer patients undergoing a treatment therapy which is different from traditional
therapy. The results of this quality improvement project also demonstrated that senior
adult participants diagnosed with cancer reported improved quality of life with no
side/adverse effects. IV C can be administered to adult patients who were diagnosed with
cancer without any age limit (Appendix E).
A limitation of this study was the smaller sample size. It is recommended that this study
be repeated with a larger sample size to improve the outcome of statistically significant
results.
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Conclusion
This quality improvement project was implemented to determine if the use of IV
C therapy used for treatment in cancer patients would prevent the most frequently
reported side/adverse effects reported in traditional treatment. It was noted that, IV C can
be used for the treatment of cancer. Although a limitation in the study was a small sample
size, the result showed that the use of IV C with and without traditional treatment
therapy, is effective in reducing side/adverse effects (Fatigue, pain, nausea/vomiting) in
cancer patients.
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Table 1. Sample EORTC QLQ-C30 Questionnaire tool
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Table 2. Demographics
Gender, Age, Race/Ethnicity, Types of Cancer, Treatment type, Comorbidities
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Appendix C
Table. 3
Mean, Standard Deviation, and Sample Size for Treatment outcome by Treatment type

Variable
M
Treatment Outcome
CAM
0.92
CAM/Traditional 0.85

SD

n

SEm

Min

Max

Skewness Kurtosis

0.02
0.04

13
7

0.00
0.01

0.92
0.80

0.95
0.89

-0.14
-0.55

-0.91
-1.25
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Table. 4

Histogram showing quality of life with IV C therapy
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